Mather Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Mather Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100	Closed	-$1.85K	–	1709
2024 Q2	$1.85K	Buy	+100	New	+$1.61K	﹤0.01%	1906

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Mather Group's ACAD Position: Q3 2024 in Review

Mather Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 100 shares — an estimated $1.85K sold.

Mather Group first reported a position in ACAD in Q2 2024 and held it in 1 quarter. The position peaked at $1.85K in Q2 2024. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

Mather Group reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Mather Group sold 100 Acadia Pharmaceuticals shares in Q3 2024, an estimated $1.85K.
Mather Group first reported a position in Acadia Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Mather Group's Acadia Pharmaceuticals position peaked at $1.85K in Q2 2024.
256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.